Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Authors
Keywords
-
Journal
Brain Sciences
Volume 12, Issue 12, Pages 1612
Publisher
MDPI AG
Online
2022-11-25
DOI
10.3390/brainsci12121612
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alterations in pain processing circuitries in episodic migraine
- (2022) Tiffani J. Mungoven et al. JOURNAL OF HEADACHE AND PAIN
- Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model
- (2022) Amélie Descheemaeker et al. BRAIN
- Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD
- (2022) Andrew M Strassman et al. CEPHALALGIA
- Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review
- (2022) Jéssica Barreto Ribeiro dos Santos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- How does a physician decide which pharmacotherapeutic option to select for acute migraine attacks?
- (2022) Elena P. Calandre et al. EXPERT OPINION ON PHARMACOTHERAPY
- Real world considerations for newly approved CGRP receptor antagonists in migraine care
- (2022) Damiana Scuteri et al. Expert Review of Neurotherapeutics
- Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling
- (2022) Jeffrey L Woodhead et al. TOXICOLOGICAL SCIENCES
- The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease
- (2022) Fulye Argunhan et al. Frontiers in Physiology
- New Generation Gepants: Migraine Acute and Preventive Medications
- (2022) David Moreno-Ajona et al. Journal of Clinical Medicine
- Cardiovascular Disease and Migraine: Are the New Treatments Safe?
- (2022) Jennifer Robblee et al. Current Pain and Headache Reports
- A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine
- (2022) Andreas A. Argyriou et al. Expert Review of Neurotherapeutics
- Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
- (2022) Pepa Polavieja et al. JOURNAL OF HEADACHE AND PAIN
- Beyond its anti‐migraine properties, sumatriptan is an anti‐inflammatory agent: A systematic review
- (2021) Moein Ala et al. DRUG DEVELOPMENT RESEARCH
- Pathophysiological Bases of Comorbidity in Migraine
- (2021) Claudia Altamura et al. Frontiers in Human Neuroscience
- Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
- (2021) Abhijeet Jakate et al. HEADACHE
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Ubrogepant in the Acute Management of Migraine: A Narrative Review
- (2021) Chia-Chun Chiang et al. Journal of Pain Research
- CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
- (2021) Matilde Capi et al. Journal of Clinical Medicine
- Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments
- (2021) Farzin Zobdeh et al. BRITISH JOURNAL OF PHARMACOLOGY
- CGRP receptor antagonists for migraine. Are they also AMY 1 receptor antagonists?
- (2021) Michael L. Garelja et al. BRITISH JOURNAL OF PHARMACOLOGY
- Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
- (2021) Todd J Schwedt et al. CEPHALALGIA
- Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
- (2021) Zaira Maraia et al. Journal of Clinical Medicine
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine
- (2021) Chun-Pai Yang et al. JAMA Network Open
- Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
- (2020) Kathleen Mullin et al. NEUROLOGY
- Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review
- (2020) Alicia Potter DeFalco et al. ANNALS OF PHARMACOTHERAPY
- Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
- (2020) Gary Berman et al. HEADACHE
- Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
- (2020) Agustin Melo-Carrillo et al. CEPHALALGIA
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
- (2020) Robert Croop et al. LANCET
- Burden of Neurological Disorders Across the US From 1990-2017
- (2020) et al. JAMA Neurology
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ubrogepant for the Treatment of Migraine
- (2019) David W. Dodick et al. NEW ENGLAND JOURNAL OF MEDICINE
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
- (2017) Antoine Daina et al. Scientific Reports
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- (2016) Tiffini Voss et al. CEPHALALGIA
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
- (2014) T. W. Ho et al. NEUROLOGY
- Costs associated with outpatient, emergency room and inpatient care for migraine in the USA
- (2011) Ralph P Insinga et al. CEPHALALGIA
- Randomized, controlled trial of telcagepant for the acute treatment of migraine
- (2009) K. M. Connor et al. NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started